Related Experiment Videos
[Local treatment of purulent chronic otitis media with ciprofloxacin]
L Podoshin1, A Brodzki, M Fradis
1Dept. of Otolaryngology, Head and Neck Surgery, Bnai-Zion Medical Center, Technion, Haifa.
Abstract:
We evaluated the efficacy of ciprofloxacin eardrops compared to tobramycin and to a placebo in the treatment of chronic suppurative otitis media. 60 ears were randomly assigned to treatment for 3 weeks with ciprofloxacin, tobramycin or placebo eardrops. The organism most commonly isolated from the ear discharge was Pseudomonas aeruginosa. The clinical responses were 78.9% and 72.2%, respectively, in the ciprofloxacin and tobramycin groups, while it was only 41.2% in the placebo group. Treatment with ciprofloxacin eardrops seemed to be at least as efficient as treatment with tobramycin. Considering the lack of ototoxicity of ciprofloxacin, this treatment may be best for chronic otitis media.
Insights
Ciprofloxacin eardrops effectively treated chronic suppurative otitis media, showing similar efficacy to tobramycin but with a better safety profile. This makes ciprofloxacin a potentially superior option for managing this ear infection.
Area of Science:
- Otolaryngology
- Infectious Diseases
- Pharmacology
Background:
- Chronic suppurative otitis media (CSOM) is a persistent middle ear infection.
- Pseudomonas aeruginosa is a common pathogen in CSOM.
- Effective and safe topical treatments are crucial for managing CSOM.
Purpose of the Study:
- To compare the efficacy of ciprofloxacin eardrops versus tobramycin eardrops and placebo for treating CSOM.
- To evaluate the clinical response rates in patients with CSOM receiving different topical antibiotic treatments.
Main Methods:
- A randomized controlled trial involving 60 ears with CSOM.
- Treatment groups received ciprofloxacin, tobramycin, or placebo eardrops for 3 weeks.
- Clinical response and causative organisms (primarily Pseudomonas aeruginosa) were assessed.
Main Results:
- Ciprofloxacin achieved a 78.9% clinical response rate.
- Tobramycin achieved a 72.2% clinical response rate.
- Placebo resulted in a significantly lower response rate of 41.2%.
Conclusions:
- Ciprofloxacin eardrops demonstrate comparable efficacy to tobramycin for CSOM treatment.
- Ciprofloxacin offers a favorable safety profile, notably lacking ototoxicity.
- Ciprofloxacin represents a potentially optimal therapeutic choice for chronic suppurative otitis media.